Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

Results 1-10 of 14 (Search time: 0.014 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2011The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferationVandyke, K.; Fitter, S.; Zannettino, A.
2017HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1Vandyke, K.; Zeissig, M.; Hewett, D.; Martin, S.; Mrozik, K.; Cheong, C.; Diamond, P.; To, L.; Gronthos, S.; Peet, D.; Croucher, P.; Zannettino, A.
2010Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?Fitter, S.; Vandyke, K.; Schultz, C.; White, D.; Hughes, T.; Zannettino, A.
2016Identification of novel EZH2 targets regulating osteogenic differentiation in mesenchymal stem cellsHemming, S.; Cakouros, D.; Vandyke, K.; Davis, M.; Zannettino, A.; Gronthos, S.
2014Engineering interaction between bone marrow derived endothelial cells and electrospun surfaces for artificial vascular graft applicationsAhmed, F.; Dutta, N.; Zannettino, A.; Vandyke, K.; Choudhury, N.
2017The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cellsVuckovic, S.; Vandyke, K.; Rickards, D.; McCauley Winter, P.; Brown, S.; Mitchell, T.; Liu, J.; Lu, J.; Askenase, P.; Yuriev, E.; Capuano, B.; Ramsland, P.; Hill, G.; Zannettino, A.; Hutchinson, A.
2017DNA barcoding reveals habitual clonal dominance of myeloma plasma cells in the bone marrow microenvironmentHewett, D.; Vandyke, K.; Lawrence, D.; Friend, N.; Noll, J.; Geoghegan, J.; Croucher, P.; Zannettino, A.
2017Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stressWallington-Beddoe, C.; Bennett, M.; Vandyke, K.; Davies, L.; Zebol, J.; Moretti, P.; Pitman, M.; Hewett, D.; Zannettino, A.; Pitson, S.
2010The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivoVandyke, K.; Dewar, A.; Diamond, P.; Fitter, S.; Schultz, C.; Sims, N.; Zannettino, A.
2010Dysregulation of bone remodeling by imatinib mesylateVandyke, K.; Fitter, S.; Dewar, A.; Hughes, T.; Zannettino, A.